New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions (Q38282800)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

1 reference

Europe PubMed Central

New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

0 references

1 reference

ChEBI release 2020-05-28

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

3

object named as

Naoya Sakamoto

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

author name string

Makoto Chuma

1

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Katsumi Terashita

2

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

publication date

4 December 2014

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Hepatology Research

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

E1-E11

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Epidemiology of viral hepatitis and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Liver resection and transplantation in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning.

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Angiogenesis and Tumor Metastasis

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration.

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

What brings pericytes to tumor vessels?

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Raf: a strategic target for therapeutic development against cancer

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

The role of signaling pathways in the development and treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Identification of a Competitive HGF Antagonist Encoded by an Alternative Transcript

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Targeting the HGF/c-Met axis: state of play.

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Angiogenesis in liver disease

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Novel advancements in the management of hepatocellular carcinoma in 2008.

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Des-γ-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1111/HEPR.12459

21 January 2018

Identifiers

10.1111/HEPR.12459

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38282800&oldid=1751912481"